These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis. Howlin RP; Cathie K; Hall-Stoodley L; Cornelius V; Duignan C; Allan RN; Fernandez BO; Barraud N; Bruce KD; Jefferies J; Kelso M; Kjelleberg S; Rice SA; Rogers GB; Pink S; Smith C; Sukhtankar PS; Salib R; Legg J; Carroll M; Daniels T; Feelisch M; Stoodley P; Clarke SC; Connett G; Faust SN; Webb JS Mol Ther; 2017 Sep; 25(9):2104-2116. PubMed ID: 28750737 [TBL] [Abstract][Full Text] [Related]
9. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Smith S; Ratjen F; Remmington T; Waters V Cochrane Database Syst Rev; 2020 May; 5(5):CD006961. PubMed ID: 32412092 [TBL] [Abstract][Full Text] [Related]
10. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2017 Jun; 6(6):CD006961. PubMed ID: 28628280 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of antibiotic efficacy against infections caused by planktonic or biofilm cultures of Pseudomonas aeruginosa and Klebsiella pneumoniae in Galleria mellonella. Benthall G; Touzel RE; Hind CK; Titball RW; Sutton JM; Thomas RJ; Wand ME Int J Antimicrob Agents; 2015 Nov; 46(5):538-45. PubMed ID: 26364845 [TBL] [Abstract][Full Text] [Related]
12. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473 [TBL] [Abstract][Full Text] [Related]
13. Bisbenzamidine and Bisbenzguanidine Ureas Act as Antibacterial Agents against Pseudomonas aeruginosa. Kellogg CN; Pugh BA; Starr IM; Parmar DJ; Troxler AD; Wolfe AL ChemMedChem; 2023 Dec; 18(24):e202300496. PubMed ID: 37806962 [TBL] [Abstract][Full Text] [Related]
14. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis. Waters V; Ratjen F Cochrane Database Syst Rev; 2008 Jul; (3):CD006961. PubMed ID: 18646176 [TBL] [Abstract][Full Text] [Related]
15. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Saiman L Paediatr Respir Rev; 2007 Sep; 8(3):249-55. PubMed ID: 17868923 [TBL] [Abstract][Full Text] [Related]
17. Antibiotic susceptabilities of Pseudomonas aeruginosa isolates derived from patients with cystic fibrosis under aerobic, anaerobic, and biofilm conditions. Hill D; Rose B; Pajkos A; Robinson M; Bye P; Bell S; Elkins M; Thompson B; Macleod C; Aaron SD; Harbour C J Clin Microbiol; 2005 Oct; 43(10):5085-90. PubMed ID: 16207967 [TBL] [Abstract][Full Text] [Related]
18. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response. Ciofu O APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model. Gómez-Junyent J; Benavent E; Sierra Y; El Haj C; Soldevila L; Torrejón B; Rigo-Bonnin R; Tubau F; Ariza J; Murillo O Int J Antimicrob Agents; 2019 May; 53(5):612-619. PubMed ID: 30682497 [TBL] [Abstract][Full Text] [Related]
20. Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model. Bilal H; Bergen PJ; Kim TH; Chung SE; Peleg AY; Oliver A; Nation RL; Landersdorfer CB Antimicrob Agents Chemother; 2019 Nov; 63(11):. PubMed ID: 31427301 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]